Company History

2023
· The antimicrobial peptide PL-18 new drug project has obtained clinical approval from the National Drug Administration

2022
· Peceleganan spray was approved by FDA to proceed phase II clinical trials in the United States
· Antimicrobial peptide PL-18 suppository approved for first human clinical study in Australia
· Antimicrobial peptide PL-18 suppository approved for first human clinical study in Australia

2021
· Establishment of ProteLight Medical Holdings (Hong Kong) Co., Ltd. (wholly-owned overseas business subsidiary)
· Establishment of ProteLight Phamaceuticals (Australia) Pty Ltd (wholly-owned overseas business subsidiary)
· Establishment of ProteLight Phamaceuticals (Australia) Pty Ltd (wholly-owned overseas business subsidiary)

2020
· Established Nanjing Denovo Pharmaceutical Technology Co., Ltd. (wholly-owned research and development subsidiary)
· Established Jiangsu Putai Pharmaceutical Technology Co., Ltd. (wholly-owned subsidiary of daily health care products)
· Established Jiangsu Putai Pharmaceutical Technology Co., Ltd. (wholly-owned subsidiary of daily health care products)

2019
· ProteLight Pharmaceutical Industry Base Officially Launched
· Honored the title of "Potential Unicorn Enterprise in Jiangsu Province"
· Honored the title of "Wuxi Quasi Unicorn Enterprise"
· Honored the title of "Potential Unicorn Enterprise in Jiangsu Province"
· Honored the title of "Wuxi Quasi Unicorn Enterprise"

2017
· Peceleganan spray project and the antimicrobial peptide PL-18 suppository project were both selected for the "13th Five Year Plan" project of the national "major new drug development" science and technology key project
· Honored the "Innovation and Entrepreneurship Award Team" in Jiangsu Province
· Honored the "Innovation and Entrepreneurship Award Team" in Jiangsu Province

2016
· Peceleganan spray obtained clinical approval for new drugs, becoming the first antimicrobial peptide innovative drug to enter human clinical trials in China

2014
· Selected by Ernst&Young as the "2014 Most Promising Seed Enterprise in China"

2012
· Peceleganan Spray Project was selected for the "12th Five Year Plan" project of the national key scientific and technological special project of "major new drug development"

2011
· Jiangsu ProteLight officially acquires Changchun ProteLight as a wholly-owned research and development subsidiary

2009
· Jiangsu ProteLight Pharmaceutical Biotechnology Co., Ltd. was officially established

2006
· Changchun ProteLight Pharmaceutical Biotechnology Co., Ltd was officially established
